Clareo Health | Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ViiV Healthcare
Age
13–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Prior participation in study APV30005 AND one of the following studies: APV30001, APV30002, AZL30006, APV30003.
Must be failing virologically (\>1000 copies at two consecutive time-points) and have a screening genotype with evidence of at least one new APV-associated protease mutation: V32I (+/- I47V), I50V, I54L/M, I84V acquired since commencing treatment with GW433908.
You may not be if
Have 2 or more of the primary resistance mutations D30N, G48V, V82A/F/T/S and L90M.
Have a medical need for use of an non-nucleoside reductase transferase inhibitor (NNRTI).
Have an acute CDC Class C event requiring therapeutic intervention.
Are pregnant or lactating.
Have any other condition which in the opinion of the investigator would preclude their participation.
